GLORIA

GEOMAR Library Ocean Research Information Access

You have 0 saved results.
Mark results and click the "Add To Watchlist" link in order to add them to this list.

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Springer Science and Business Media LLC  (3)
  • van Leeuwen, Pim J.  (3)
  • 1
    In: EJNMMI Research, Springer Science and Business Media LLC, Vol. 12, No. 1 ( 2022-12)
    Abstract: High urinary activity in urinary bladder and ureters may hamper interpretation of prostate cancer and regional nodal metastases in prostate-specific membrane antigen (PSMA) PET/CT. The goal of this study was to assess effects of furosemide and choice of tracer on urinary activity in the bladder and ureters, as well as on occurrence of peri-bladder artefacts in PET/CT. Methods Four cohorts with a total of 202 men staged with PSMA PET/CT for prostate cancer received either 68 Ga-PSMA-11 as tracer, with (cohort G+) or without 10mg intravenous furosemide (G−) concurrent with tracer, or 18 F-DCFPyL with (F+) or without furosemide (F−). SUVmax of bladder and ureters, presence, type, and severity of peri-bladder artefacts were compared between cohorts. The influence of furosemide and choice of tracer was determined while taking differences in biodistribution time into account. Results Median SUVmax bladder was 43,5; 14,8; 61,7 and 22,8 in cohorts G−, G+, F− and F+, respectively, resulting in significant overall ( p  〈  0.001) and between cohort differences ( p adjusted 〈  0.001 to 0.003) except between G− and F+. Median SUVmax ureter was 6.4; 4.5; 8.1 and 6.0 in cohorts G−, G+, F− and F+, respectively, resulting in significant overall ( p  〈  0.001) and between cohort differences for G+ : F− and F− : F+ ( p  〈  0.001, respectively, 0.019). Significant effects of furosemide and choice of tracer on SUVmax bladder ( p  〈  0.001 resp. p  = 0.001) and of furosemide on SUVmax ureter ( p  〈  0.001) were found, whereas differences in biodistribution time had not impacted these results significantly. Peri-bladder artefacts were present in 42/202 (21%) patients and were significantly more frequent in the F− cohort, respectively, less frequent in the G+ cohort ( p  = 0.001 resp. p  〈  0.001). Peri-bladder artefacts had a direct positive correlation with SUVmax bladder ( p  = 0.033). Conclusions Increased urinary activity and higher incidence of peri-bladder artefacts were found in 18 F-DCFPyL compared to 68 Ga-PSMA-11 PET/CT. Effective reduction of urinary activity may be reached through forced diuresis using 10mg intravenous furosemide, which is especially advantageous in 18 F-DCFPyL PET/CT.
    Type of Medium: Online Resource
    ISSN: 2191-219X
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2022
    detail.hit.zdb_id: 2619892-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Tijdschrift voor Urologie, Springer Science and Business Media LLC, Vol. 11, No. 1 ( 2021-01), p. 2-10
    Abstract: We created a model predicting the probability to detect prostate cancer recurrence outside the prostatic fossa in men with biochemical recurrence (BCR) after radical prostatectomy (RP). 419 patients with BCR (prostate specific antigen [PSA] 〈  2.0 ng/ml) after RP without hormone therapy underwent a 68 Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computer Tomograpy (PET/CT)-scan. Predictors for the detection of prostate cancer recurrence outside the prostatic fossa were identified using multivariable logistic regression analysis. At a median PSA of 0,40 ng/ml (interquartile range 0,30–0,70), PSMA PET/CT detected prostate cancer recurrence outside the prostatic fossa in 174 (42%) patients. Significant predictors for the detection of prostate cancer recurrence outside the prostatic fossa were PSA value at time of scanning and RP specimen characteristics Gleason-score, lymph node status and surgical margin status. PSA value at time of scanning and RP specimen characteristics, Gleason-score, lymph node status and surgical margin status are all important predictors for the probability to detect prostate cancer recurrence outside the prostatic fossa. The dashboard ( https://psma.prostatecancer-riskcalculator.com/ ) can be used to determine the clinical most optimal moment to perform a PSMA PET/CT scan.
    Type of Medium: Online Resource
    ISSN: 2211-3037 , 2211-4718
    Language: Dutch
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2021
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: BMC Cancer, Springer Science and Business Media LLC, Vol. 20, No. 1 ( 2020-12)
    Abstract: To evaluate the impact of Gallium-68 [ 68 Ga] labeled prostate specific membrane antigen (PSMA) positron emission tomography (PET)/X-ray computed tomography (CT) compared with conventional imaging on staging and clinical management of men evaluated for primary prostate cancer (PCa). Methods Men with newly diagnosed biopsy-proven PCa who had been staged with a conventional staging protocol including bone scintigraphy (BS) and additionally underwent [ 68 Ga]PSMA PET/CT, were evaluated retrospectively. Imaging findings from BS, magnetic resonance imaging (MRI) and/or CT were categorized regarding locoregional nodal (N) and distant metastasis (M) status as negative, positive or equivocal before and after addition of the information of PET/CT. Also, the imaging-based level of confidence (LoC) in correct assessment of N and M status was scored. Impact of PET/CT on clinical management was evaluated by the percentage of treatment category changes after PET/CT as determined in the multidisciplinary tumour board. Results Sixty-four men with intermediate and high-risk PCa were evaluated. With additional information of PET/CT, N status was upstaged in 23%, and downstaged in 9%. M status was upstaged in 13%, and downstaged in 23%. A net increase in LoC of 20% was noted, mainly regarding M status. Treatment category changed from palliative to curative in 9%, and from curative to palliative in 3%. An undecided treatment plan changed to curative in 14%, as well as to palliative in another 9%. In total, a 36% treatment category change was noted. High negative predictive value of PET/CT for M status was indicated by 27 patients that underwent robot-assisted radical prostatectomy and reached postoperative biochemical disease-free status or had a likely other site of disease recurrence. Conclusions PSMA PET/CT can cause considerable changes in N and M staging, as well as in management compared to conventional staging. Findings of this study support the replacement of BS and CT by PSMA PET/CT in staging primary PCa.
    Type of Medium: Online Resource
    ISSN: 1471-2407
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2020
    detail.hit.zdb_id: 2041352-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...